ERBB2 and neoplasm: Based on the analysis of large, randomised studies14, once a decision is taken, based on several considerations such as patient’s age, histology, tumour grade and proliferation, to offer an ER positive, HER2 negative patient preoperative chemotherapy, the latter should be given for a sufficient period of time, probably in the order of 6 months.3 Our findings reassure us on the benefit of a longer chemotherapy duration with the inherent toxicities.